Stay updated on Nivolumab and Relatlimab in MMRd Cancers Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to evaluating the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
    Difference
    0.1%
    Check dated 2024-06-06T15:56:29.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed description of eligibility criteria, including examples such as a person's general health condition or prior treatments. The new text also directs users to 'Learn About Studies' for general information about clinical research.
    Difference
    26%
    Check dated 2024-05-22T11:46:27.000Z thumbnail image
  8. Check
    41 days ago
    Change Detected
    Summary
    The value 'Go to the classic website Go to the classic website 5 2' on the webpage has been updated to 'type of intervention Site Map 6 0'. This change likely indicates a modification related to medical and healthcare-related publications and documentation.
    Difference
    1%
    Check dated 2024-05-02T17:34:22.000Z thumbnail image

Stay in the know with updates to Nivolumab and Relatlimab in MMRd Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.